866-997-4948(US-Canada Toll Free)

Dyslipidemia - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 280 Pages

Dyslipidemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Dyslipidemia - Overview 11
Dyslipidemia - Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 25
Dyslipidemia - Therapeutics Assessment 26
Assessment by Target 26
Assessment by Mechanism of Action 30
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Dyslipidemia - Companies Involved in Therapeutics Development 38
Acasti Pharma Inc 38
Akcea Therapeutics Inc 38
Allergan Plc 39
Amgen Inc 39
Arisaph Pharmaceuticals Inc 40
AstraZeneca Plc 40
BASF SE 41
BCWorld Pharm Co Ltd 41
BioRestorative Therapies Inc 42
Boryung Pharmaceutical Co Ltd 42
Cadila Pharmaceuticals Ltd 43
Cardax Inc 43
Catabasis Pharmaceuticals Inc 44
Celon Pharma SA 44
Cerenis Therapeutics Holding SA 45
Chong Kun Dang Pharmaceutical Corp 45
CJ HealthCare Corp 46
Connexios Life Sciences Pvt Ltd 46
CymaBay Therapeutics Inc 47
Daewoong Pharmaceutical Co Ltd 47
Daiichi Sankyo Company Ltd 48
Eli Lilly and Company 48
Esperion Therapeutics Inc 49
Gemphire Therapeutics Inc 49
Gilead Sciences Inc 50
GlaxoSmithKline Plc 50
Golden Biotechnology Corp 51
HanAll Biopharma Co Ltd 51
Hanmi Pharmaceuticals Co Ltd 52
Huons Co Ltd 52
Hyundai Pharmaceutical Co Ltd 53
Innovent Biologics Inc 53
IPCA Laboratories Ltd 54
Jeil Pharmaceutical Co Ltd 54
Jenrin Discovery Inc 55
JW Pharmaceutical Corp 55
Kissei Pharmaceutical Co Ltd 56
Kotobuki Pharmaceutical Co Ltd 56
Kowa Company Ltd 57
Kuhnil Pharmaceutical Co Ltd 57
Kyorin Pharmaceutical Co Ltd 58
Lipicard Technologies Ltd 58
Lipigon Pharmaceuticals AB 59
LipimetiX Development Inc 59
Lotus Pharmaceutical Co Ltd 60
Matinas BioPharma Holdings Inc 60
Merck & Co Inc 61
Nippon Chemiphar Co Ltd 61
Omeros Corp 62
Pfizer Inc 62
Pharmena SA 63
Protalix BioTherapeutics Inc 63
Regeneron Pharmaceuticals Inc 64
Samjin Pharmaceutical Co Ltd 64
Sancilio & Company Inc 65
Takeda Pharmaceutical Company Ltd 65
Tasly Pharmaceutical Group Co Ltd 66
Torrent Pharmaceuticals Ltd 66
Yuhan Corp 67
Zydus Cadila Healthcare Ltd 67
Dyslipidemia - Drug Profiles 68
(amlodipine besylate + fimasartan + rosuvastatin calcium) - Drug Profile 68
(amlodipine besylate + olmesartan medoxomil) + rosuvastatin calcium - Drug Profile 69
(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 70
(amlodipine besylate + rosuvastatin calcium) - Drug Profile 71
(amlodipine besylate + valsartan)+ atorvastatin calcium - Drug Profile 72
(amlodipine maleate + rosuvastatin calcium + telmisartan) - Drug Profile 73
(atorvastatin calcium + choline fenofibrate) - Drug Profile 74
(atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 75
(atorvastatin calcium + metformin hydrochloride XR) - Drug Profile 76
(atorvastatin calcium IR + losartan potassium DR) - Drug Profile 77
(candesartan cilexetil + rosuvastatin calcium) - Drug Profile 78
(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79
(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 80
(nebivolol hydrochloride + rosuvastatin calcium) - Drug Profile 81
(pitavastatin + valsartan) - Drug Profile 82
4655-K09 - Drug Profile 83
AC-261066 - Drug Profile 84
AEM-28 - Drug Profile 85
AEM-2802 - Drug Profile 87
AEM-2814 - Drug Profile 88
ALN-AC3 - Drug Profile 89
ALN-ANG - Drug Profile 90
AMG-899 - Drug Profile 91
anacetrapib - Drug Profile 93
Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 95
antroquinonol - Drug Profile 96
ARGX-116 - Drug Profile 98
ARI-3037MO - Drug Profile 99
bempedoic acid - Drug Profile 101
bezafibrate SR - Drug Profile 113
BioE-1115 - Drug Profile 115
BKC-007 - Drug Profile 116
BSN-272 - Drug Profile 117
C-3 - Drug Profile 118
CAT-2000 Series - Drug Profile 119
CAT-2003 - Drug Profile 120
CDR-267F018 - Drug Profile 123
CDX-085 - Drug Profile 124
centatin - Drug Profile 127
CER-209 - Drug Profile 128
CKD-519 - Drug Profile 129
CNX-013B2 - Drug Profile 131
DF-461 - Drug Profile 132
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 133
DS-9001 - Drug Profile 134
DWJ-1330 - Drug Profile 136
etanercept biosimilar - Drug Profile 137
evinacumab - Drug Profile 139
gemcabene calcium - Drug Profile 141
GSK-2041706 - Drug Profile 145
HCP-1105 - Drug Profile 146
HOB-071 - Drug Profile 147
HU-012 - Drug Profile 148
IBI-306 - Drug Profile 149
icosabutate - Drug Profile 150
IMMH-007 - Drug Profile 152
IONIS-ANGPTL3LRx - Drug Profile 153
IONIS-APOCIIILRX - Drug Profile 155
JD-2000 Series - Drug Profile 156
JD-5000 Series - Drug Profile 157
JD-5006 - Drug Profile 158
JD-5037 - Drug Profile 159
JD-6000 Series - Drug Profile 160
JS-002 - Drug Profile 161
K-312 - Drug Profile 162
KI-1107 - Drug Profile 163
KKM-1201 - Drug Profile 164
KT-6971 - Drug Profile 165
KTA-439 - Drug Profile 166
leucine + niacin - Drug Profile 167
liothyronine sodium - Drug Profile 168
LP-071 - Drug Profile 169
LT-5421 - Drug Profile 170
LT-5423 - Drug Profile 171
LTPO-3FA - Drug Profile 172
LY-3202328 - Drug Profile 173
MAT-9001 - Drug Profile 174
metformin hydrochloride + rosuvastatin calcium - Drug Profile 176
MN-002 - Drug Profile 177
NC-2400 - Drug Profile 179
ND-630 - Drug Profile 180
ND-654 - Drug Profile 182
NKPL-66 - Drug Profile 185
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 190
omega-3-carboxylic acids - Drug Profile 191
pemafibrate - Drug Profile 196
peroxibrate - Drug Profile 199
PF-06427878 - Drug Profile 200
Protein for Dislipidemia, Obesity and Type 2 Diabetes - Drug Profile 201
Recombinant ApoE4 for Dyslipidemia - Drug Profile 202
REGN-1001 - Drug Profile 203
saroglitazar - Drug Profile 204
SC-401 - Drug Profile 207
seladelpar - Drug Profile 208
SJP-1603 - Drug Profile 212
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 213
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 214
Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile 215
Small Molecule for Cardiovascular and Metabolic Diseases - Drug Profile 216
Small Molecule for Hypertriglyceridaemia - Drug Profile 217
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 218
Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 219
Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 220
Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 221
Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile 222
Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile 223
Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 224
Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease - Drug Profile 225
Small Molecules to Target GPR146 for Metabolic Disorders - Drug Profile 226
SPX-8522876 - Drug Profile 227
Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile 228
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 230
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 231
TRC-210258 - Drug Profile 232
TRIA-662 - Drug Profile 233
TSL-1516 - Drug Profile 235
volanesorsen sodium - Drug Profile 236
ZLN-005 - Drug Profile 243
ZLN-024 - Drug Profile 244
ZYH-7 - Drug Profile 245
Dyslipidemia - Dormant Projects 246
Dyslipidemia - Discontinued Products 255
Dyslipidemia - Product Development Milestones 259
Featured News & Press Releases 259
Appendix 271
Methodology 271
Coverage 271
Secondary Research 271
Primary Research 271
Expert Panel Validation 271
Contact Us 271
Disclaimer 272

List of Tables
Number of Products under Development for Dyslipidemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2017
Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2017
Dyslipidemia - Pipeline by Allergan Plc, H1 2017
Dyslipidemia - Pipeline by Amgen Inc, H1 2017
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2017
Dyslipidemia - Pipeline by BASF SE, H1 2017
Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2017
Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
Dyslipidemia - Pipeline by Cardax Inc, H1 2017
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
Dyslipidemia - Pipeline by Celon Pharma SA, H1 2017
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Dyslipidemia - Pipeline by CJ HealthCare Corp, H1 2017
Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H1 2017
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2017
Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H1 2017
Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H1 2017
Dyslipidemia - Pipeline by Gilead Sciences Inc, H1 2017
Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2017
Dyslipidemia - Pipeline by Golden Biotechnology Corp, H1 2017
Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Dyslipidemia - Pipeline by Huons Co Ltd, H1 2017
Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Innovent Biologics Inc, H1 2017
Dyslipidemia - Pipeline by IPCA Laboratories Ltd, H1 2017
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Jenrin Discovery Inc, H1 2017
Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H1 2017
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Kowa Company Ltd, H1 2017
Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H1 2017
Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H1 2017
Dyslipidemia - Pipeline by LipimetiX Development Inc, H1 2017
Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
Dyslipidemia - Pipeline by Merck & Co Inc, H1 2017
Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
Dyslipidemia - Pipeline by Omeros Corp, H1 2017
Dyslipidemia - Pipeline by Pfizer Inc, H1 2017
Dyslipidemia - Pipeline by Pharmena SA, H1 2017
Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H1 2017
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Dyslipidemia - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
Dyslipidemia - Pipeline by Sancilio & Company Inc, H1 2017
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
Dyslipidemia - Pipeline by Yuhan Corp, H1 2017
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Dyslipidemia - Dormant Projects, H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..2), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..3), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..4), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..5), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..6), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..7), H1 2017
Dyslipidemia - Dormant Projects, H1 2017 (Contd..8), H1 2017
Dyslipidemia - Discontinued Products, H1 2017
Dyslipidemia - Discontinued Products, H1 2017 (Contd..1), H1 2017
Dyslipidemia - Discontinued Products, H1 2017 (Contd..2), H1 2017
Dyslipidemia - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures
Number of Products under Development for Dyslipidemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *